Teva Pharmaceutical Industries Limited (TEVA) : The value of composite uptick trades was $38.27 million, whereas, the value of composite downtick trades was $93.67 million. The uptick to downtick ratio stood at 0.41 with a negative money flow of ($55.41) Million during Mondays trading session. The block trades money flow was negative ($52.61 million).The uptick to the downtick ratio of 0.02 in block trades signals that the large investors have utilized the rise in the stock to sell.The uptick transaction value stood at $1.33 million. The transaction of the trades on downticks amounted to $53.94 million, which confirms investors selling on the strength of price. Teva Pharmaceutical Industries Limited (TEVA) gained 44 cents at $53.86, an increase of 0.82% over the previous days close.
Shares of Teva Pharmaceutical Industries Limited rose by 2.42% in the last five trading days and 0.61% for the last 4 weeks. Teva Pharmaceutical Industries Limited is up 8.87% in the last 3-month period. Year-to-Date the stock performance stands at -15.85%.
Teva Pharmaceutical Industries Limited (NYSE:TEVA): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $54.26 and $53.89 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $55.39. The buying momentum continued till the end and the stock did not give up its gains. It closed at $54.54, notching a gain of 1.26% for the day. The total traded volume was 8,082,659 . The stock had closed at $53.86 on the previous day.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.